Clinical Research of Kangshi Kangxian Recipe Treating on Hepatic Fibrosis of Chronic Hepatitis B

目的观察康氏抗纤方治疗慢性乙型肝炎肝纤维化的临床疗效,探讨其对肝组织N-花生四烯酸氨基乙醇(; arachidonoylethanolamine,AEA) 、2-花生四烯酸甘油( 2-arachidonoylglycerol,2-AG); 、大麻素受体1( cannabinoid receptor 1,CBR1) mRNA、大麻素受体2( cannabinoid receptor; 1,CBR2); mRNA含量变化的影响。方法将110例慢性乙型肝炎肝纤维化患者按随机数字表法分为治疗组和对照组,每组55例。治疗组予中药康氏抗纤方联合恩替卡韦分; 散片治疗,对照组用恩替卡韦分散片单药治疗,两组均治疗48周。判定两组临床疗效,检测血清ALT水平,HBV; DNA、HBsAg、HBsAb定量,肝组织病理、肝硬度变化,肝组织AEA、 2-AG含量和CBR1、CBR2; mRNA表达水平。结果与对照组比较,治疗组的临床总有效率、HBsAg阴转率、肝组织纤维化分期疗效有效率均高于对照组(chi~2 =; 4.453,4.152,6.364,均P < 0.05); 。与本组治疗前比较,治疗后两组患者肝纤维化瞬时弹性测定值、AEA、2-AG含量及CBR1、CBR2 mRNA表达均降低(均P <; 0.05),且治疗组降低更明显(均P < 0.05); 。肝组织病理显示:治疗后治疗组肝小叶结构基本完整,肝细胞轻度水样变性,汇管区纤维组织无增生,局部少量淋巴细胞浸润,炎症及纤维化较对照组明显改善。; 结论康氏抗纤方具有提高慢性乙型肝炎肝纤维化患者的临床总有效率、HBsAg阴转率、肝组织纤维化分期疗效有效率,其作用机制可能与调节内源性大麻素系统; 有关。Objective To observe the clinical effect of Kangshi Kangxian Decoction (; KSKXD) in treating on patients of hepatic fibrosis of chronic hepatitis; B ( CHB),and to explore the mechanisms of KSKXD by regulating the; contents of arachidonoylethanolamine ( AEA),2-arachidonoylglycerol (; 2-AG),cannabinoid receptor 1 ( CBR1 mRNA) and cannabinoid receptor 2 (; CBR2 mRNA) in the liver tissue. Methods Totally 110 patients with; hepatic fibrosis of CHB were assigned to the treatment group and the; control group according to random digit table,55 cases in each group.; The treatment group was treated with Chinese herb KSKXD combined with; Entecavir,and the control group was treated with Entecavir. Both of the; two groups were treated for 48 weeks. The clinical efficacy of the two; groups was determined. The serum ALT levels,HBV DNA, HBsAg and HBsAb; quantification,liver pathological changes,liver stiffness; changes,contents of AEA and 2-AG,mRNA expression of CBR1 and CBR2 in the; liver tissue were detected. Results The total effective rate,HBsAg; negative conversion rate,hepatic fibrosis staging and curative effect; rate of the treatment group were higher than those of the control group; (chi~2 = 4.453,4.152,6.364,allP <0.05). After treatment,the; instantaneous elasticity of liver fibrosis,the contents of AEA and; 2-AG,the mRNA expressions of CBR1 and CBR2 in the liver tissue in the; two groups were decreased compared to those of the same group before; treatment (P < 0.05),and the treatment group had better effect than that; of the control group (P < 0.05). The pathological changes in the; treatment group after treatment indicated the liver lobules; integrity,mild hydropic degeneration of liver cells,periportal fibrous; tissue hyperplasia,local small lymphocytic infiltration,which fibrosis; and inflammation were better than those of the control group.; Conclusions KSKXD was effective in the treatment of hepatic fibrosis of; CHB, which improved total effective rate,HBsAg seroconversion rate and; liver fibrosis stage efficiency. And its mechanism maybe related to the; regulation of the endocannabinoid system.国家自然科学基金资助项目; 福建省科技计划引导性项目; 厦门市科技惠民项目; 福建中医药大学临床专项校管课题基

科学技術振興調整費プログラムオフィサーの役割と課題(科学技術政策)

一般論

Preparation of Pd/TiO2/C Catalyst and Its Electrocatalytic Performance in Basic Solution for Ethanol Oxidation

钛酸四丁酯前驱体水热合成制备纳米TiO2颗粒，在TiO2和Vulcan XC-72活性炭复合载体上液相还原负载Pd纳米颗粒，制得Pd/TiO2/C复合催化剂. 通过透射电镜（TEM）和X射线衍射（XRD）测试表明其具有面心立方结构，Pd金属粒子（粒径约3 ~ 4 nm）均匀分散在锐钛矿型的纳米TiO2和活性碳的复合载体上. 循环伏安和计时电流曲线测试表明，与相同Pd载量的Pd/C相比，20% Pd载量的Pd/TiO2/C颗粒在常温常压下对乙醇的电催化氧化有很高活性和稳定性. 这主要归功于纳米TiO2改变了Pd表面的电子特性，且增大了其比表面积.Nanoparticles TiO2 were prepared by hydrothermal method using precursor tetrabutyl titanate. The Pd/TiO2/C catalyst was synthesized by liquid phase reducing method supported on nano TiO2 and Vulcan carbon XC-72. The Pd/TiO2/C catalyst was characterized by XRD, TEM, cyclic voltammetry, and chronopotentiometry. XRD confirmed the face-centered cubic structure of Pd particles, and TEM indicated that Pd particles (size 3 ~ 4 nm) dispersed uniformly on TiO2 and carbon XC-72. The results from cyclic voltammogram and chronopotentiogram showed the higher ethanol oxidation activity and stability of Pd/TiO2/C catalyst (20% Pd) as compared with those of Pd/C catalyst at ambient temperature and pressure in alkaline media. The improved properties in Pd/TiO2/C catalyst (20% Pd) might mainly due to the presence of TiO2 nanoparticles which changed the electron properties on Pd surface and increased the electrochemical surface area.国家自然科学基金项目（No. 21103107）和上海市科委能力建设项目（No. 10160502300）资助作者联系地址：上海电力学院上海高校电力腐蚀控制与应用电化学重点实验室，上海 200090Author's Address: Key laboratory of Shanghai Colleges and Universities for Electric Power Corrosion Control and Applied Electrochemistry, Shanghai University of Electric Power, Shanghai 200090, China通讯作者E-mail：[email protected]

重离子束流横向剂量分布测量探测器及其二维成像方法

本发明涉及重离子束(包括质子束)治疗肿瘤技术的领域，尤其涉及到重离子束流横向剂量分布测量探测器及其二维成像方法，其主要特点是包括气体密封腔(1)，其内设有电离室内芯(2)，与电离室内芯(2)电连接的多路信号转接板(3)；所述的气体密封腔(1)由主体框架(1-1)和入射窗(1-2)、出射窗(1-3)组成；所述的电离室内芯(2)由两组电离室单元组成，每个单元电离室均由信号极(2-1)、绝缘垫板(2-2)和高压极(2-3)组成；所述的多路信号转接板(3)的一端设有接触端(3-3)插入气体密封腔(1)的密封口(1-5)与电离室内芯(2)的信号极(2-1)相连，另一端设有多芯连接器(3-2)为束流剖面监测探测器的信号输出端口

Progress in Design and Fabrication of Current and Helium Feeding System for JT-60SA Superconducting Coils

To realize JT-60SA of the largest superconducting tokamak device in the world, the current feeder, helium piping and control system have been designed. In order to reduce the reaction force of support, crank shaped feeder and piping were designed. The crank shaped feeder reduces the reaction force of support to 10% of zigzag shaped feeder. Because of the limited space in torus hall, many interfaces of feeder and piping are located at upper part of tokamak. Feeders and piping have to manage large displacement of interface by adding bending. One box type electrical joint was developed with good reproducibility of electrical resistance below 3 nΩ even though different connecting positions and manufactures. Five coil terminal boxes, eleven valve boxes, components of cryoline and control system were manufactured already. These components will be installed in torus hall in 2019.第27回核融合エネルギー会